506 related articles for article (PubMed ID: 18573340)
1. Immunogenic cancer cell death: a key-lock paradigm.
Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
[TBL] [Abstract][Full Text] [Related]
2. Molecular characteristics of immunogenic cancer cell death.
Tesniere A; Panaretakis T; Kepp O; Apetoh L; Ghiringhelli F; Zitvogel L; Kroemer G
Cell Death Differ; 2008 Jan; 15(1):3-12. PubMed ID: 18007663
[TBL] [Abstract][Full Text] [Related]
3. Human tumor cells killed by anthracyclines induce a tumor-specific immune response.
Fucikova J; Kralikova P; Fialova A; Brtnicky T; Rob L; Bartunkova J; Spísek R
Cancer Res; 2011 Jul; 71(14):4821-33. PubMed ID: 21602432
[TBL] [Abstract][Full Text] [Related]
4. The immunogenicity of tumor cell death.
Kepp O; Tesniere A; Zitvogel L; Kroemer G
Curr Opin Oncol; 2009 Jan; 21(1):71-6. PubMed ID: 19125021
[TBL] [Abstract][Full Text] [Related]
5. Immunogenic cell death modalities and their impact on cancer treatment.
Kepp O; Tesniere A; Schlemmer F; Michaud M; Senovilla L; Zitvogel L; Kroemer G
Apoptosis; 2009 Apr; 14(4):364-75. PubMed ID: 19145485
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic death of colon cancer cells treated with oxaliplatin.
Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
[TBL] [Abstract][Full Text] [Related]
7. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Criollo A; Ortiz C; Lidereau R; Mariette C; Chaput N; Mira JP; Delaloge S; André F; Tursz T; Kroemer G; Zitvogel L
Immunol Rev; 2007 Dec; 220():47-59. PubMed ID: 17979839
[TBL] [Abstract][Full Text] [Related]
8. Ecto-calreticulin in immunogenic chemotherapy.
Obeid M; Tesniere A; Panaretakis T; Tufi R; Joza N; van Endert P; Ghiringhelli F; Apetoh L; Chaput N; Flament C; Ullrich E; de Botton S; Zitvogel L; Kroemer G
Immunol Rev; 2007 Dec; 220():22-34. PubMed ID: 17979837
[TBL] [Abstract][Full Text] [Related]
9. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.
Zappasodi R; Pupa SM; Ghedini GC; Bongarzone I; Magni M; Cabras AD; Colombo MP; Carlo-Stella C; Gianni AM; Di Nicola M
Cancer Res; 2010 Nov; 70(22):9062-72. PubMed ID: 20884630
[TBL] [Abstract][Full Text] [Related]
10. Witch hunt against tumor cells enhanced by dendritic cells.
Locher C; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Kroemer G; Zitvogel L
Ann N Y Acad Sci; 2009 Sep; 1174():51-60. PubMed ID: 19769736
[TBL] [Abstract][Full Text] [Related]
11. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.
Apetoh L; Tesniere A; Ghiringhelli F; Kroemer G; Zitvogel L
Cancer Res; 2008 Jun; 68(11):4026-30. PubMed ID: 18519658
[TBL] [Abstract][Full Text] [Related]
12. [Immunological aspects of anticancer chemotherapy].
Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
[TBL] [Abstract][Full Text] [Related]
13. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity.
Brusa D; Garetto S; Chiorino G; Scatolini M; Migliore E; Camussi G; Matera L
Vaccine; 2008 Nov; 26(50):6422-32. PubMed ID: 18848858
[TBL] [Abstract][Full Text] [Related]
14. High hydrostatic pressure induces immunogenic cell death in human tumor cells.
Fucikova J; Moserova I; Truxova I; Hermanova I; Vancurova I; Partlova S; Fialova A; Sojka L; Cartron PF; Houska M; Rob L; Bartunkova J; Spisek R
Int J Cancer; 2014 Sep; 135(5):1165-77. PubMed ID: 24500981
[TBL] [Abstract][Full Text] [Related]
15. HMGB1: a two-headed signal regulating tumor progression and immunity.
Campana L; Bosurgi L; Rovere-Querini P
Curr Opin Immunol; 2008 Oct; 20(5):518-23. PubMed ID: 18599281
[TBL] [Abstract][Full Text] [Related]
16. The 'kiss of death' by dendritic cells to cancer cells.
Chan CW; Housseau F
Cell Death Differ; 2008 Jan; 15(1):58-69. PubMed ID: 17948029
[TBL] [Abstract][Full Text] [Related]
17. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Dong Xda E; Ito N; Lotze MT; Demarco RA; Popovic P; Shand SH; Watkins S; Winikoff S; Brown CK; Bartlett DL; Zeh HJ
J Immunother; 2007 Sep; 30(6):596-606. PubMed ID: 17667523
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic anti-cancer chemotherapy as an emerging concept.
Haynes NM; van der Most RG; Lake RA; Smyth MJ
Curr Opin Immunol; 2008 Oct; 20(5):545-57. PubMed ID: 18573339
[TBL] [Abstract][Full Text] [Related]
19. Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells--A Key Role for Heat-Shock Protein 70 and Receptor CD91.
Salimu J; Spary LK; Al-Taei S; Clayton A; Mason MD; Staffurth J; Tabi Z
Cancer Immunol Res; 2015 Jun; 3(6):678-88. PubMed ID: 25678582
[TBL] [Abstract][Full Text] [Related]
20. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity.
Bianchi ME; Manfredi AA
Immunol Rev; 2007 Dec; 220():35-46. PubMed ID: 17979838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
